Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.

Karnon J, Tolley K, Vieira J, Chandiwana D.

Clin Drug Investig. 2012 Dec;32(12):805-15. doi: 10.1007/s40261-012-0008-2.

PMID:
23026844
2.
3.

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.

Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R.

Curr Med Res Opin. 2008 Jun;24(6):1609-21. doi: 10.1185/03007990802077442. Epub 2008 Apr 24.

PMID:
18439348
4.

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.

Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q.

J Med Econ. 2010;13(3):559-70. doi: 10.3111/13696998.2010.516203.

PMID:
20812793
5.

Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.

Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.

Transfusion. 2013 Aug;53(8):1722-9. doi: 10.1111/trf.12024. Epub 2012 Dec 12.

PMID:
23241074
6.

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.

Ho WL, Chung KP, Yang SS, Lu MY, Jou ST, Chang HH, Yang YL, Lin DT, Lin KH.

J Formos Med Assoc. 2013 Apr;112(4):221-9. doi: 10.1016/j.jfma.2011.08.020. Epub 2012 Apr 30.

7.

Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.

Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P.

Clin Drug Investig. 2011;31(7):493-505. doi: 10.2165/11587120-000000000-00000.

PMID:
21627338
8.

Deferasirox for managing iron overload in people with thalassaemia.

Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.

Cochrane Database Syst Rev. 2017 Aug 15;8:CD007476. doi: 10.1002/14651858.CD007476.pub3. Review.

9.

Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.

Bentley A, Gillard S, Spino M, Connelly J, Tricta F.

Pharmacoeconomics. 2013 Sep;31(9):807-22. doi: 10.1007/s40273-013-0076-z. Erratum in: Pharmacoeconomics. 2013 Dec;31(12):1185-6.

10.

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.

Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010. Review.

11.

Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.

Imran F, Phatak P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):297-304. doi: 10.1586/erp.09.26.

PMID:
19670988
12.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.

Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450. doi: 10.1002/14651858.CD004450.pub3. Review.

PMID:
23963793
13.

Current status of iron overload and chelation with deferasirox.

Choudhry VP, Naithani R.

Indian J Pediatr. 2007 Aug;74(8):759-64. Review.

PMID:
17785900
14.

A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea.

Kim J, Kim Y.

Value Health. 2009 Nov-Dec;12 Suppl 3:S78-81. doi: 10.1111/j.1524-4733.2009.00633.x. Erratum in: Value Health. 2010 Mar;13(2):336.

16.

Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.

Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, Cuccia L, Spasiano A, Filosa A, Caruso V, Hanif A, Meloni A.

Clin Drug Investig. 2017 May;37(5):453-464. doi: 10.1007/s40261-017-0496-1.

PMID:
28185140
17.

Deferasirox for managing iron overload in people with thalassaemia.

Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD007476. doi: 10.1002/14651858.CD007476.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Aug 15;8:CD007476.

PMID:
22336831
18.

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.

Clin Ther. 2007 May;29(5):909-17.

PMID:
17697909
19.

Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.

Cappellini MD, Taher A.

Expert Opin Pharmacother. 2008 Sep;9(13):2391-402. doi: 10.1517/14656566.9.13.2391 . Review.

PMID:
18710363
20.

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).

Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; CORDELIA study investigators.

Blood. 2014 Mar 6;123(10):1447-54. doi: 10.1182/blood-2013-04-497842. Epub 2014 Jan 2.

Supplemental Content

Support Center